微卫星不稳定性
彭布罗利珠单抗
DNA错配修复
肿瘤科
临床终点
不利影响
队列
医学
临床试验
外科
内科学
微卫星
癌症
免疫疗法
基因
等位基因
结直肠癌
生物化学
化学
作者
Jianming Xu,Yimin Mao,Nong Xu,Yuxian Bai,Dong Wang,Xiaojun Chen,Xianli Yin,Yanhong Deng,Jun Yang,Jieqing Zhang,Jie Tang,Yi Wen Huang,Jiayi Li,Liangyu Bie,Hong Zheng,Weidong Zhao,Miaomiao Xu,Nan Li,Mao Ye,Alexander Gozman,Xiaohua Wu
出处
期刊:Immunotherapy
[Future Medicine]
日期:2024-03-20
标识
DOI:10.2217/imt-2023-0294
摘要
Aim: To evaluate pembrolizumab in patients of Chinese descent with microsatellite instability-high (MSI-H)/deficient mismatch repair (dMMR) tumors enrolled in KEYNOTE-158 (Cohort L). Methods: Patients with MSI-H/dMMR advanced tumors received pembrolizumab 200 mg IV Q3W. Primary end point was overall response rate (ORR). Secondary end points were duration of response (DOR), progression-free survival (PFS) and overall survival (OS). Results: 24 patients were enrolled (20 were evaluable for efficacy). With median follow-up of 12.4 months, the ORR was 70%. DOR, PFS and OS were all not reached. A total of 19 (79%) patients had a treatment-related adverse event (AE; grade ≥3 in 4 [17%]), and 8 (33%) had an immune-mediated AE (grade ≥3 in (4 [17%]). Conclusion: Pembrolizumab provided meaningful and durable responses with manageable safety. These results are consistent with those reported for the global trial.
科研通智能强力驱动
Strongly Powered by AbleSci AI